Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given an average rating of “Hold” by the fourteen research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $15.05.
Several analysts recently weighed in on IRWD shares. Morgan Stanley set a $13.00 price objective on Ironwood Pharmaceuticals and gave the company a “hold” rating in a report on Friday, May 3rd. Mizuho set a $20.00 price objective on Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 2nd. Credit Suisse Group set a $16.00 target price on Ironwood Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, March 22nd. BidaskClub downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Finally, HC Wainwright set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, June 24th.
Ironwood Pharmaceuticals stock traded up $0.13 during midday trading on Monday, hitting $10.94. The stock had a trading volume of 3,559,797 shares, compared to its average volume of 1,232,720. The company has a market capitalization of $1.67 billion, a PE ratio of -11.52 and a beta of 1.79. Ironwood Pharmaceuticals has a 12 month low of $9.07 and a 12 month high of $21.20. The business’s fifty day moving average is $10.88.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.10). The company had revenue of $68.73 million during the quarter, compared to analysts’ expectations of $81.93 million. The firm’s revenue was down .6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.25) earnings per share. On average, research analysts predict that Ironwood Pharmaceuticals will post -0.02 earnings per share for the current fiscal year.
In other Ironwood Pharmaceuticals news, CFO Gina Consylman sold 4,055 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $10.53, for a total value of $42,699.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.90% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $63,000. Gotham Asset Management LLC acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $135,000. NumerixS Investment Technologies Inc acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $190,000. Financial Counselors Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $204,000. Finally, Bank of Montreal Can boosted its position in shares of Ironwood Pharmaceuticals by 426.9% during the fourth quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock worth $175,000 after buying an additional 13,649 shares during the period. Institutional investors and hedge funds own 98.89% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Further Reading: How are institutional investors different from individual investors?
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.